Jacobs Levy Equity Management’s Celldex Therapeutics CLDX Stock Holding History

Jacobs Levy Equity Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,933	Closed	-$15K	–	998
2018 Q2	$15K	Sell	1,933 -15,074	-89%	-$201K	﹤0.01%	1011
2018 Q1	$594K	Buy	17,007 +4,234	+33%	+$164K	0.01%	750
2017 Q4	$544K	Buy	12,773 +5,026	+65%	+$215K	0.01%	735
2017 Q3	$332K	Buy	7,747 +1,967	+34%	+$73.7K	0.01%	772
2017 Q2	$214K	Buy	5,780 +1,673	+41%	+$74K	﹤0.01%	824
2017 Q1	$222K	Buy	+4,107	New	+$214K	﹤0.01%	773
2016 Q3	–	Sell	-9,127	Closed	-$601K	–	1026
2016 Q2	$601K	Sell	9,127 -53	-0.6%	-$3.37K	0.01%	707
2016 Q1	$521K	Buy	+9,180	New	+$1.03M	0.01%	715

Other funds holding CLDX

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jacobs Levy Equity Management's CLDX Position: Q3 2018 in Review

Jacobs Levy Equity Management sold out of Celldex Therapeutics (CLDX) in Q3 2018, closing a stake of 1,933 shares — an estimated $15K sold.

Jacobs Levy Equity Management first reported a position in CLDX in Q1 2016 and held it in 8 quarters. The position peaked at $601K in Q2 2016. 95 funds tracked by Wall St. Rank hold CLDX as of Q3 2018.

Jacobs Levy Equity Management reported no remaining Celldex Therapeutics position as of Q3 2018 after selling out during the quarter.
Jacobs Levy Equity Management sold 1,933 Celldex Therapeutics shares in Q3 2018, an estimated $15K.
Jacobs Levy Equity Management first reported a position in Celldex Therapeutics in Q1 2016 and held it in 8 quarters.
Jacobs Levy Equity Management's Celldex Therapeutics position peaked at $601K in Q2 2016.
95 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.